Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma
Sheila F. Faraj(Howard Hughes Medical Institute), George J. Netto(University of Pennsylvania), Charles G. Drake(Columbia University Irving Medical Center), Janis M. Taube(Bloomberg (United States)), Güneş Güner(Johns Hopkins University), Robert A. Anders(Johns Hopkins University), Jessica Hicks(Johns Hopkins University), Trinity J. Bivalacqua(University of Pennsylvania), Mark Schoenberg(Montefiore Medical Center), Enrico Munari(University of Brescia), Alan K. Meeker(Johns Hopkins University)
Cited by 184
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k